Opinion

Video

Infection Prevention and Leveraging EHR for Bispecific Therapy Management

Key Takeaways

  • Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
  • Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
SHOW MORE

Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).

Video content above is prompted by the following

  • What best practices can you share regarding preventing infection in patients receiving bispecific therapies in RRMM?
  • How has your institution leveraged the electronic health record to assist with standardization and management of toxicities seen with bispecific therapies?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously
5 experts in this video
5 experts in this video